CA
VKTX icon

Crewe Advisors’s Viking Therapeutics VKTX Stock Holding History

Crewe Advisors’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-8,322
Closed -$219K – 1131
2025
Q3 		$219K Hold
8,322
– – 0.02% 197
2025
Q2 		$221K Hold
8,322
– – 0.03% 143
2025
Q1 		$201K Hold
8,322
– – 0.03% 134
2024
Q4 		$335K Sell
8,322
-8,044
-49% -$459K 0.05% 108
2024
Q3 		$1.04M Buy
+16,366
New +$960K 0.12% 54

Other funds holding VKTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Crewe Advisors's VKTX Position: Q4 2025 in Review

Crewe Advisors sold out of Viking Therapeutics (VKTX) in Q4 2025, closing a stake of 8,322 shares — an estimated $219K sold.

Crewe Advisors first reported a position in VKTX in Q3 2024 and held it in 5 quarters. The position peaked at $1.04M in Q3 2024. 426 funds tracked by Wall St. Rank hold VKTX as of Q4 2025.

  • Crewe Advisors reported no remaining Viking Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Crewe Advisors sold 8,322 Viking Therapeutics shares in Q4 2025, an estimated $219K.
  • Crewe Advisors first reported a position in Viking Therapeutics in Q3 2024 and held it in 5 quarters.
  • Crewe Advisors's Viking Therapeutics position peaked at $1.04M in Q3 2024.
  • 426 funds tracked by Wall St. Rank held Viking Therapeutics as of Q4 2025.

Based on Crewe Advisors's 13F filing for Q4 2025, filed 16 Jan 2026.